Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder

BACKGROUND: Vibegron is a new β3-adrenergic receptor agonist which has been demonstrated for the treatment of overactive bladder (OAB). We carried out meta-analysis to evaluate the efficiency of vibegron vs antimuscarinic monotherapy for treating OAB. METHODS: Randomized controlled trials (RCTs) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Shunye, Liang, Liqin, Lin, Jinlei, Liu, Ludong, Chen, Zhipeng, Gao, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870164/
https://www.ncbi.nlm.nih.gov/pubmed/33592817
http://dx.doi.org/10.1097/MD.0000000000023171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870164/
https://www.ncbi.nlm.nih.gov/pubmed/33592817
http://dx.doi.org/10.1097/MD.0000000000023171

Ejemplares similares